Syed A. Hussain
A5031306593- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Multiple and Secondary Primary Cancers
- Urological Disorders and Treatments
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Cancer Research and Treatments
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Gastrointestinal disorders and treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Gallbladder and Bile Duct Disorders
- Fibroblast Growth Factor Research
- Gastrointestinal Bleeding Diagnosis and Treatment
- Liver Disease Diagnosis and Treatment
- Colorectal Cancer Screening and Detection
University of Sheffield
2000-2025
Sheffield Teaching Hospitals NHS Foundation Trust
2020-2025
University of Kansas
2025
University of Tennessee at Knoxville
2025
Community Health Center
2022-2025
University of Liverpool
2012-2024
Weston Park Cancer Centre
2020-2024
NYU Langone Health
2024
Jinnah Postgraduate Medical Center
2024
Sher-e-Kashmir University of Agricultural Sciences and Technology of Kashmir
2024
Prostate cancer is a heterogeneous disease, but current treatments are not based on molecular stratification. We hypothesized that metastatic, castration-resistant prostate cancers with DNA-repair defects would respond to poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibition olaparib.
Radiotherapy is an alternative to cystectomy in patients with muscle-invasive bladder cancer. In other disease sites, synchronous chemoradiotherapy has been associated increased local control and improved survival, as compared radiotherapy alone.
Hepatocellular carcinoma is a common complication of chronic liver disease (CLD), and conventionally diagnosed by radiological means. We aimed to build statistical model that could determine the risk hepatocellular in individual patients with CLD using objective measures, particularly serological tumor markers.A total 670 either alone or were recruited from single UK center into case-control study. Sera collected prospectively specifically for this A logistic regression analysis was used...
Cabozantinib is an inhibitor of kinases, including MET and vascular endothelial growth factor receptors, has shown activity in men with previously treated metastatic castration-resistant prostate cancer (mCRPC). This blinded phase III trial compared cabozantinib prednisone patients mCRPC.Men progressive mCRPC after docetaxel abiraterone and/or enzalutamide were randomly assigned at a two-to-one ratio to 60 mg once per day or 5 twice day. The primary end point was overall survival (OS). Bone...
Robot-assisted radical cystectomy is being performed with increasing frequency, but it unclear whether total intracorporeal surgery improves recovery compared open for bladder cancer.
Purpose To establish whether maintenance lapatinib after first-line chemotherapy is beneficial in human epidermal growth factor receptor (HER) 1/HER2–positive metastatic urothelial bladder cancer (UBC). Methods Patients with UBC were screened centrally for HER1/HER2 overexpression. who positive HER1/2 and did not have progressive disease during (four to eight cycles) randomly assigned one or placebo completion of first-line/initial disease. The primary end point was progression-free survival...
Little is known about health-related quality of life (HRQOL) following treatment for bladder cancer (BC). To determine this, we undertook a cross-sectional survey covering 10% the English population. Participants 1–10 yr from diagnosis were identified through national registration data. A postal was administered containing generic HRQOL and BC-specific outcome measures. Findings compared with those general population other pelvic patients. Generic measured using five-level EQ-5D (EQ-5D-5L)...
BC2001, the largest randomised trial of bladder-sparing treatment for muscle-invasive bladder cancer (MIBC), demonstrated improvement in locoregional control by adding fluorouracil and mitomycin C to radiotherapy (James ND, Hussain SA, Hall E, et al. Radiotherapy with or without chemotherapy cancer. N Engl J Med 2012;366:1477-88). There are limited data on long-term recurrence risk.
Pituitary tumorigenesis is a poorly understood process involving dysregulation of the cell cycle, proliferation, and angiogenesis. The novel securin pituitary tumor transforming gene (PTTG) disrupts division stimulates fibroblast growth factor (FGF)-2-mediated We investigated expression angiogenic vascular endothelial (VEGF) its receptor KDR/Flk-1 in 103 human tumors, we assessed functional relationships between these genes vitro. Nonfunctioning tumors (n = 81) demonstrated markedly raised...
Abstract —Hyperhomocysteinemia is associated with endothelial dysfunction, although its mechanism unknown. Isometric tension recordings and lucigenin chemiluminescence were used to assess the effects of homocysteine exposure on endothelium-dependent -independent relaxation in isolated rabbit aortic rings superoxide anion (O 2 − ) production by cultured porcine cells, respectively. Homocysteine (0.1 10 mmol/L) produced a significant ( P <0.001) concentration- time-dependent inhibition...
Tumour hypoxia is a microenvironmental factor related to poor response radiation, chemotherapy, genetic instability, selection for resistance apoptosis, and increased risk of invasion metastasis. Hypoxia-regulated carbonic anhydrase IX (CA IX) has been studied in various tumour sites its expression correlated with the clinical outcome. The purpose this study was investigate correlation CA outcome patients invasive breast cancer. We conducted retrospective examining effects on survival To...
BACKGROUND Gemcitabine plus cisplatin (GC) has been adopted as a neoadjuvant regimen for muscle‐invasive bladder cancer despite the lack of Level I evidence in this setting. METHODS Data were collected using an electronic data‐capture platform from 28 international centers. Eligible patients had clinical T‐classification 2 (cT2) through cT4aN0M0 urothelial and received GC or methotrexate, vinblastine, doxorubicin, (MVAC) before undergoing cystectomy. Logistic regression was used to compute...
To test whether reducing radiation dose to uninvolved bladder while maintaining the tumor would reduce side effects without impairing local control in treatment of muscle-invasive cancer.
In previous work, it is suggested that the excessive amount of fatty acids transported by FABP5 may facilitate malignant progression prostate cancer cells through a FABP5-PPARγ-VEGF signal transduction axis to increase angiogenesis. To further functionally characterise pathway, we have, in this investigated molecular mechanisms involved its tumorigenicity promoting role cancer. Suppression PPARγ highly produced significant reduction (up 53%) their proliferation rate, invasiveness 89%) and...
<h3>Importance</h3> DCVAC/PCa is an active cellular immunotherapy designed to initiate immune response against prostate cancer. <h3>Objective</h3> To evaluate the efficacy and safety of plus chemotherapy followed by maintenance treatment in patients with metastatic castration-resistant cancer (mCRPC). <h3>Design, Setting, Participants</h3> The VIABLE double-blind, parallel-group, placebo-controlled, phase 3 randomized clinical trial enrolled mCRPC among 177 hospital clinics US Europe between...
Treatment options are limited for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) disease recurrence after bacillus Calmette-Guérin (BCG) treatment and who ineligible for/refuse radical cystectomy. FGFR alterations commonly detected in NMIBC. We evaluated the activity of oral erdafitinib, a selective pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, versus intravesical chemotherapy NMIBC select FGFR3/2 following BCG treatment.